三生制药(01530)盘中走强，午后维持高位，最新报7.7港元，涨4.05%，成交额1.58亿港元。大摩发研报指，由于在疫情下内地药品集中采购实施日期进一步推迟等，预期三生制药今年的销售增长目标会由10%以下，调升至双位数；至于盈利因汇兑收益影响，估计会增长20%至30%。该行将三生制药目标价由6.2港元升21%至7.5港元，评级维持“与大市同步”，并调升集团今年至2024年销售预测分别5%、6%及7%。
三生制药(01530)盘中走强，午后维持高位，最新报7.7港元，涨4.05%，成交额1.58亿港元。大摩发研报指，由于在疫情下内地药品集中采购实施日期进一步推迟等，预期三生制药今年的销售增长目标会由10%以下，调升至双位数；至于盈利因汇兑收益影响，估计会增长20%至30%。该行将三生制药目标价由6.2港元升21%至7.5港元，评级维持“与大市同步”，并调升集团今年至2024年销售预测分别5%、6%及7%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.